마더스제약

본문 바로가기

A passionate company
that changes without fear and constantly challenges itself”

Mother’s Pharmaceutical contributes to creating a healthy life and society for patients through the development and supply of excellent pharmaceutical products. The company has achieved continuous growth by focusing on specialized talent development, systematic research and development, and expansion of its sales network. Mother’s is committed to challenging itself in the development of new pharmaceutical products to pioneer the future.

Through our unwavering efforts,we aim to become one of the top pharmaceutical companies in South Korea, taking responsibility for public health and contributing to society.

Company name Mother’s Pharmaceutical Co., Ltd
Date of establishment July 18th, 2011
CEO Jwa Jin Kim
Main areas of business Manufacture and sale of pharmaceuticals
Paid in capital

6,191,516,000(202312)

Number of employees 268 (’22 Q4)
Address 501 ho, 51 Boramae-ro 5-gil, Dongjak-gu, Seoul, South Korea
Phone/Fax 02) 6958-8660 / 02) 6958-8665

Main Operating Sites

Gyeongsan Manufacturing Plant
Gyeongsan Manufacturing Plant is a KGMP factory with a focus on producing oral solid products. Since its inception in 2011, the KGMP factory continuously invested in equipment and expansion for high level of optimization. Based on the accumulated technology and expertise, the factory supplies safe and high-quality pharmaceutical products.
Gyeongsan Manufacturing Plant
Iksan Manufacturing Plant is a KGMP factory with a floor area of 9,444 square meters and a site measuring 38,361 square meters that was completed in 2021. It is a smart factory equipped with the latest production equipment such as a fluidized bed dryer and a double cone mixer, as well as an automation system. Based on a production capacity that is twice that of the existing factory, it efficiently produces high-quality pharmaceuticals.
Research and Development Center
Mother's Pharmaceutical's R&D center consists of a New Drug Development Research Institute that focuses on developing new drugs, as well as a Product Development Research Institute that focuses on developing incrementally modified drugs and generics. These institutes work together in an organic cooperation.